- <![CDATA[Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer]]><![CDATA[The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer. ]]>onclive · 2mo ago↗ source
- Drugmakers have to go through rigorous tests to get a lower tariff rateLanding a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive…Endpoints · 2mo ago↗ source
- <![CDATA[Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade]]><![CDATA[A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses. ]]>